hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06268041 id: 427659 id: R01HD093694 type: NIH link: https://reporter.nih.gov/quickSearch/R01HD093694 briefTitle: HIT-Stroke Trial 2 acronym: HST2 overallStatus: RECRUITING date: 2024-02-09 date: 2028-01 date: 2028-04 date: 2024-02-20 date: 2024-02-20 name: University of Cincinnati class: OTHER name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) name: University of Kansas Medical Center name: University of Delaware briefSummary: People who had a stroke at least 6 months prior and who still have difficulty with walking will each be randomly assigned to receive either moderate or vigorous intensity walking exercise. Both protocols will be performed individually with a physical therapist for 45 minutes, 3x/week for 12 weeks. Measures including walking function will be assessed at baseline (PRE), after 4, 8 and 12 weeks of training (12WK) and at 3-month follow up (3moPOST), by raters who are unaware of the participant randomization. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 156 type: ESTIMATED name: Moderate-Intensity Aerobic Training name: High-Intensity Interval Training measure: 6-Minute Walk Test Distance measure: 6-Minute Walk Test Distance measure: Self-Selected Gait Speed measure: Fastest Gait Speed measure: PROMIS-Fatigue Scale version 8a measure: Aerobic Capacity measure: EuroQol-5D-5L sex: ALL minimumAge: 30 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Delaware status: RECRUITING city: Newark state: Delaware zip: 19713 country: United States name: Jane Diehl role: CONTACT email: strokestudies@udel.edu name: Darcy Reisman, PT, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.68372 lon: -75.74966 facility: University of Kansas Medical Center status: RECRUITING city: Kansas City state: Kansas zip: 66160 country: United States name: Sasha Moores role: CONTACT phone: 913-588-2697 email: reachlab@kumc.edu name: Sandra Billinger, PT, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.11417 lon: -94.62746 hasResults: False
nctId: NCT06268028 id: BELMA TA briefTitle: Discharge Training Given to Primiparous Mothers Who Had a Cesarean Delivery overallStatus: ENROLLING_BY_INVITATION date: 2024-01-10 date: 2024-06-10 date: 2024-11-10 date: 2024-02-20 date: 2024-02-21 name: Aydin Adnan Menderes University class: OTHER briefSummary: This study aimed to determine the effect of discharge training given to primiparous mothers who gave birth by cesarean section on the level of readiness for discharge.
The research is a pre-test-post-test, randomized controlled experimental study. conditions: Education studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 70 type: ESTIMATED name: Training measure: A pre-test will be applied to 70 women who constitute the sample of the research. measure: Apost-test will be applied to 70 women who constitute the sample of the research. sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Aydın Maternity and Child Health Hospital city: Aydın zip: 09010 country: Turkey lat: 37.84501 lon: 27.83963 hasResults: False
nctId: NCT06268015 id: Pro00115311 briefTitle: Botensilimab and Balstilimab Optimization in Colorectal Cancer acronym: BBOpCo overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2028-07 date: 2028-07 date: 2024-02-20 date: 2024-02-22 name: Nicholas DeVito, MD class: OTHER name: Gateway for Cancer Research name: Agenus Inc. briefSummary: This is a single-arm, interventional, pilot clinical trial. Fifteen evaluable patients will have tumor-informed ctDNA testing at baseline and start botensilimab and balstilimab treatment. They will receive botensilimab and balstilimab in 6-week cycles until progression, after which mFOLFOX6 and bevacizumab or panitumumab will be added to the regimen. Subjects will have safety testing at baseline and every two weeks while on study drug. Study treatment with botensilimab and balstilimab, mFOLFOX6, and bevacizumab or panitumumab will be continued until radiographic or clinical progression, toxicity, or patient withdrawal. Subjects will have one safety follow up visit 30 days after the last treatment and will be followed for survival every 12 weeks for up to 2 years. conditions: Colorectal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Botensilimab name: Balstilimab name: Oxaliplatin name: Leucovorin name: Fluorouracil name: Bevacizumab name: Panitumumab measure: Disease control rate based on iRECIST at second restaging scan measure: Proportion of subjects with a best overall response of complete response or partial response according to iRECIST measure: Disease control rate based on RECIST v1.1 at second restaging scan measure: Proportion of subjects with a best overall response of complete response or partial response according to RECIST v1.1 measure: Months of overall survival measure: Months of progression-free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Duke University city: Durham state: North Carolina zip: 27710 country: United States name: Nicholas C. DeVito, MD role: PRINCIPAL_INVESTIGATOR lat: 35.99403 lon: -78.89862 hasResults: False
nctId: NCT06268002 id: 5876557033 briefTitle: Effect of Vernonia Cinerea Lozenges as a Smoking Cessation Aid in Patients With Non-communicable Diseases overallStatus: COMPLETED date: 2017-09-01 date: 2021-09-30 date: 2021-12-31 date: 2024-02-20 date: 2024-02-28 name: Chulalongkorn University class: OTHER briefSummary: Vernonia cinerea is an herbal which has been recorded in many Thai herbal formulation and Thai traditional medicine has used this herbal for treating various diseases included hypertension, asthma, fever, hepatitis, kidney stone and smoking cessation. Now aday there are more interest for using Vernonia cinerea as a medication to aid smoker to quit smoking because it is cheaper than other current therapeutic medications. The objective of this study is to evaluate efficacy and safety of Vernonia cinerea lozenge for smoking cessation when compared to placebo. conditions: Smoking Cessation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study was a multicenter randomized, paralleled, double-blind, controlled trial at 5 hospitals and 2 community pharmacies in Thailand primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 93 type: ACTUAL name: Vernonia cinerea name: Placebo measure: continuous abstinence rate measure: continuous abstinence rate (CAR) and point prevalence rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Krittin Bunditanukul city: Bangkok zip: 10600 country: Thailand lat: 13.75398 lon: 100.50144 hasResults: False
nctId: NCT06267989 id: Gothenburg University briefTitle: The Effectiveness of Early Intervention to Correct the Position of PDC:s acronym: PDC overallStatus: RECRUITING date: 2024-02-12 date: 2027-12-30 date: 2027-12-30 date: 2024-02-20 date: 2024-02-21 name: Region Örebro County class: OTHER briefSummary: Approximately 2-3% of children will have problems with one or both of their permanent or 'adult' canine teeth in the upper jaw. These canine teeth sometimes fail to erupt properly, because they are displaced into the roof of the mouth or palate. These are known as palatally displaced canines, PDC, (Brin et al., 1986, Ericson and Kurol, 1987). In addition to failing to erupt, displaced teeth can cause problems, such as damage to the roots or displacement of the neighbouring teeth (Ericson and Kurol, 1988a, Ericson and Kurol, 2000, Falahat et al., 2008).
It has been suggested that if the primary ('baby' or 'milk') canine is extracted at an appropriate time in a child with a suspected palatally displaced canine, then the displaced tooth might spontaneously correct its position (Ericson and Kurol, 1988b) and the extraction of the baby canine when a clinician suspects that the adult canine is displaced has become accepted clinical practice (Short, 2009). This appears to be on the basis of one report of a series of 35 children who received the intervention and no control group (Ericson and Kurol, 1988b). Two recent systematic reviews have examined the evidence for the effectiveness of removal of the primary canine with the aim of correcting the eruption path of a palatally displaced canine. A recent systematic review published in The Cochrane Library in 2021 (Benson et al., 2021) noted that the evidence for any intervention to correct the eruption path of a displaced permanent canine is weak and further research is required. Numerous problems with the reported studies were identified by both reviews.
Other authors have suggested that using a RME (Rapid Maxillary expansion) or headgrear (EOT) to create sufficient space within the dental arch for the permanent canine tooth will encourage the tooth to erupt (Baccetti et al., 2011). This approach might be less traumatic to a child who may have had no experience of dental treatment, other than routine check-ups. If either or both approaches are shown to be effective then their widespread use would be advantageous to both the child and the healthcare provider, because the need for an operation, under general anaesthetic, to uncover the tooth and extensive brace treatment to straighten the tooth will be avoided. conditions: Ectopic Tooth Eruption conditions: Palatal Expansion Technique conditions: Randomized Clinical Trial studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 318 type: ESTIMATED name: Extraction of the primary canine teeth name: Expansion measure: Succeful eruption of the palatally displaced canines into the dental arch measure: Cost effectiveness of the interventions measure: Prevalence and severity of damage to surrounding teeth either due to the unerupted tooth or orthodontic intervention. sex: ALL minimumAge: 10 Years maximumAge: 12 Years stdAges: CHILD facility: Gothenbrug University status: RECRUITING city: Gothenburg country: Sweden name: Farhan Bazargani, DDS, PhD role: CONTACT name: Björn Ludwig, DDS, PhD role: PRINCIPAL_INVESTIGATOR name: Martyn Coborune, DDS, PhD role: PRINCIPAL_INVESTIGATOR lat: 57.70716 lon: 11.96679 hasResults: False
nctId: NCT06267976 id: REB23-1003 briefTitle: Validation of the ProSomnus® RPMO2 Device overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2024-05-31 date: 2024-06-30 date: 2024-02-20 date: 2024-04-02 name: ProSomnus Sleep Technologies class: INDUSTRY briefSummary: The purpose of the study is to:
2. Evaluate the pulse rate performance simultaneously collected over the SpO2 range. conditions: Healthy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 15 type: ESTIMATED name: ProSomnus RPMO2 measure: SpO2 accuracy measure: Pulse rate accuracy sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: University of Calgary city: Calgary state: Alberta zip: T2N4N1 country: Canada name: Brad Hansen role: CONTACT phone: 403-210-8925 email: bhanse@ucalgary.ca lat: 51.05011 lon: -114.08529 hasResults: False
nctId: NCT06267963 id: C4391010 id: 2023-507074-40-00 type: REGISTRY domain: CTIS (EU) briefTitle: A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-31 date: 2024-04-18 date: 2024-04-18 date: 2024-02-20 date: 2024-04-16 name: Pfizer class: INDUSTRY briefSummary: The purpose of this study is to learn about how much PF-07220060 will be taken up and processed by healthy male participants.
During their stays, participants will have their blood, urine, and feces collected by the study doctors several times. We will measure the level of PF-07220060 in participants' blood, urine, and feces samples. This will help to know how much the study medicine is getting taken up by the body. At the end of the study, participants will be contacted by phone to check in. Participants will be involved in this study for about 9 weeks from the screening until the follow-up. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 12 type: ACTUAL name: Oral [14C]PF-07220060 name: Oral PF-07220060 name: IV [14C] PF-07220060 measure: Cumulative recovery (%) of radioactivity in urine and feces (adjusted for vomitus, if any), expressed as a percent of total oral radioactive dose administered. measure: Amount of metabolites of [14C]PF-07220060 in plasma, urine, and feces. measure: Dose normalized AUCinf of intravenous radiolabeled PF-07220060 in plasma (if data permit) measure: The absolute oral bioavailability (F) of PF-07220060 measure: The fraction of PF-07220060 dose absorbed (Fa) measure: Number of participants with treatment emergent clinically significant laboratory abnormalities measure: Number of participants with treatment emergent clinically significant abnormal ECG measurements measure: Number of participants with treatment emergent clinically significant abnormal vital measurements measure: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) measure: Number of participants with treatment emergent clinically significant abnormal physical examination sex: MALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: PRA Health Sciences city: Groningen zip: 9728 NZ country: Netherlands lat: 53.21917 lon: 6.56667 hasResults: False
nctId: NCT06267950 id: PILUO-INFANT briefTitle: Effect of Oral Feeding in Infants With Pierre Robin Syndrome overallStatus: RECRUITING date: 2024-02-29 date: 2024-10 date: 2024-10 date: 2024-02-20 date: 2024-03-06 name: Zeng Changhao class: OTHER briefSummary: This was a randomized controlled study. The infants enrolled were randomly divided into the IOE group (with Intermittent Oro-Esophageal Tube Feeding) and the PNG group (with Nasogastric Tube Feeding), all receiving systemic therapy. Before and after 4-week treatment, pulmonary infection, swallowing function, nutritional status and body weight between the two group were compared. conditions: Pierre Robin Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: systematic therapy name: intermittent oro-esophageal tube feeding name: gastric tube feeding measure: Number of patients diagnosed as the pulmonary infection "Positive" measure: Nutritional status-total protein measure: Nutritional status-hemoglobin measure: Nutritional status-albumin measure: Body weight measure: The Functional Oral Intake Scale for Infants sex: ALL minimumAge: 1 Month maximumAge: 12 Months stdAges: CHILD facility: Hsinchu Rehabilitation Hospital status: RECRUITING city: Xinzhu country: Taiwan name: Haim Liu, Master role: CONTACT lat: 22.46205 lon: 120.47335 hasResults: False
nctId: NCT06267937 id: 101 briefTitle: Hip Fractures in Chile: Implications for Public Health Policy and Healthcare Delivery overallStatus: COMPLETED date: 2023-03-10 date: 2023-03-10 date: 2024-01-30 date: 2024-02-20 date: 2024-02-20 name: University of Chile class: OTHER name: Instituto Sistemas Complejos de Ingeniería, Universidad de Chile, Santiago, Chile briefSummary: Hip fractures in individuals aged 60 and above pose significant challenges in terms of morbidity, mortality, and healthcare costs. While countries like the United Kingdom and Australia have optimized their healthcare systems for timely management of hip fractures, the situation in Chile presents distinct challenges due to its mixed healthcare system. This study aims to assess survival rates following hip fractures in Chile and identify associated risk factors using national databases from 2012 to 2018. A comprehensive analysis of 35,520 patients revealed that factors such as age, type of health insurance, access to surgery, and treatment in public hospitals significantly influence mortality rates after hip fractures. The study found that patients with hip fractures experience lower 5-year survival rates compared to the general population, particularly when affiliated with public insurance and treated in public institutions. Modifiable factors like delayed surgery and prolonged hospital stays contribute to increased mortality rates. The findings underscore the urgent need for optimized public health policies and healthcare delivery systems to enhance outcomes for hip fracture patients in Chile.Hip fractures in individuals aged 60 and above pose significant challenges in terms of morbidity, mortality, and healthcare costs. While countries like the United Kingdom and Australia have optimized their healthcare systems for timely management of hip fractures, the situation in Chile presents distinct challenges due to its mixed healthcare system. This study aims to assess survival rates following hip fractures in Chile and identify associated risk factors using national databases from 2012 to 2018. conditions: Hip Fractures studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 46380 type: ACTUAL name: Access to surgery name: type of intitution measure: survival after hip fracture sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: hospital Clinico Universidad de Chile city: Santiago state: Region Metropolitana zip: 8380456 country: Chile lat: -33.45694 lon: -70.64827 hasResults: False
nctId: NCT06267924 id: Olith10703 briefTitle: SENSE-VM: Safety and Effectiveness of a Novel Medical Device for Symptom Ease in Vestibular Migraines overallStatus: ENROLLING_BY_INVITATION date: 2024-02-28 date: 2024-08-31 date: 2024-09-30 date: 2024-02-20 date: 2024-03-19 name: Otolith Labs class: INDUSTRY name: MCRA briefSummary: The goal of this virtual clinical trial is to compare the effectiveness of two study devices in providing temporary relief to adults aged 18-75 who suffer from symptoms of chronic Vestibular Migraines (VM), also known as Migraine Associated Vertigo.
Researchers will compare the randomized groups to determine which group responds better to which device. conditions: Vestibular Migraine conditions: Migraine Associated Vertigo studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The proposed clinical trial for the study device will be a randomized, sham-controlled, double-blind study with two-parallel arms (active/sham device). primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 200 type: ESTIMATED name: Otoband Experimental name: Otoband Sham measure: DHI Change in Scores measure: Number of related adverse events measure: Change in number of vestibular migraine episodes weekly measure: Global Impression of Change (severity of episodes) measure: DHI change from transition to end of study measure: Device responder rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Otolith Labs city: Washington state: District of Columbia zip: 20001 country: United States lat: 38.89511 lon: -77.03637 hasResults: False
nctId: NCT06267911 id: 202223-10 id: 160/U/2022 type: OTHER_GRANT domain: Fundació La Marató de TV3 briefTitle: Rehabilitation Gaming System for Intensive Care Units acronym: RGS-ICU overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-04 date: 2026-04 date: 2024-02-20 date: 2024-04-23 name: University of the Balearic Islands class: OTHER name: Corporacion Parc Tauli name: Hospital Son Llatzer name: Fundació La Marató de TV3 briefSummary: Admission to an Intensive Care Unit (ICU) is a potentially traumatic experience for a mentally vulnerable person. Beyond the stress and anxiety associated with the ICU environment and medical procedures, survivors of critical illness are at risk of developing cognitive and psychological sequelae related to Post-Intensive Care Syndrome (PICS). These disorders are associated with high economic, medical and personal costs.
This trial aims to evaluate the efficacy of an innovative neuropsychological e-health intervention for early cognitive stimulation and psychological support of people in critical care, i.e. the Rehabilitation Gaming System for Intensive Care Units (RGS-ICU) intervention, in improving comfort during ICU admission and cognition and mental health three and 12 months after ICU discharge. The RGS-ICU intervention, applied as an adjunct to standard ICU care, is based on non-immersive virtual reality techniques and has been specifically designed and developed to suit the needs of people in critical care and the characteristics of the ICU environment. To ensure the safety of the intervention, participants' physiological parameters will be automatically recorded by advanced continuous monitoring systems as part of standard ICU care.
The RGS-ICU intervention has been designed at Corporacion Parc Taulí with the collaboration of the University of the Balearic Islands and has been developed by Eodyne Systems S.L., a company dedicated to the development of science-based technological solutions for intervention, monitoring, diagnosis, and prognosis in stroke and other brain disorders. conditions: Critical Illness studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Cognitive stimulation and psychological support (RGS-ICU) measure: Attention performance measure: Working memory performance measure: Learning/memory performance measure: Executive function performance measure: Processing speed performance measure: Incidence of Treatment-Emergent Adverse Events [Safety] measure: Dyspnea intensity measure: Pain intensity measure: Worry intensity measure: Sadness intensity measure: Comfort experienced measure: Anxiety symptoms measure: Symptoms of depression measure: Symptoms of post-traumatic stress disorder measure: Subjective cognition measure: Functionality measure: Health-related quality of life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of the Balearic Islands city: Palma De Mallorca state: Balearic Islands zip: 07122 country: Spain name: Guillem Navarra-Ventura, PhD role: CONTACT phone: +34971259888 email: g.navarra@uib.es lat: 39.56939 lon: 2.65024 facility: Hospital Universitari Son Llàtzer city: Palma De Mallorca state: Balearic Islands zip: 07198 country: Spain name: Gemma Rialp, MD, PhD role: CONTACT phone: +34871202000 email: grialp@ssib.es lat: 39.56939 lon: 2.65024 facility: Corporacion Parc Tauli city: Sabadell state: Catalonia zip: 08208 country: Spain name: Sol Fernández-Gonzalo, PhD role: CONTACT phone: +34937236673 email: msfernandez@tauli.cat lat: 41.54329 lon: 2.10942 hasResults: False
nctId: NCT06267898 id: EBMT- 842205547 briefTitle: Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML overallStatus: COMPLETED date: 2009-11-01 date: 2015-01-29 date: 2015-05-21 date: 2024-02-20 date: 2024-02-20 name: European Society for Blood and Marrow Transplantation class: NETWORK name: Novartis briefSummary: Stem cell transplantation and blood product transfusions are standard of care for Myelodysplastic Syndromes (MDS). Several studies have shown changes in serum ferritin and non-transferrin-bound iron (NTBI) in patients undergoing stem cell transplantation. A large proportion of MDS patients are at risk for organ damage from tissue siderosis, due to the development of iron overload.